新疆非小細(xì)胞肺癌患者EGFR基因表達(dá)特征及其臨床相關(guān)性研究
發(fā)布時(shí)間：2018-10-24 11:08
【摘要】：目的：探討新疆地區(qū)非小細(xì)胞肺癌患者中表皮生長(zhǎng)因子受體(EGFR)的突變情況及其與臨床病理學(xué)特征和腫瘤標(biāo)志物之間的相關(guān)性。方法：選取在新疆醫(yī)科大學(xué)第一附屬醫(yī)院行肺癌根治術(shù)后非小細(xì)胞肺癌患者51例,應(yīng)用熒光PCR法對(duì)腫瘤組織中DNA進(jìn)行EGFR基因第18、19、20、21等外顯子檢測(cè),并術(shù)前檢測(cè)血清癌胚抗原等多種腫瘤標(biāo)志物。結(jié)果：EGFR陽(yáng)性率為49.02%(25/51),其中18號(hào)外顯子突變率為8%(2/25),19號(hào)突變率為52%(13/25),21號(hào)突變率為40%(10/25),20號(hào)未檢測(cè)到突變。男性陽(yáng)性率37.5%(12/32),女性陽(yáng)性率68.42%(13/19)。女性患者陽(yáng)性率顯著高于男性,有統(tǒng)計(jì)學(xué)差異(p0.05),腺癌和腺鱗癌與鱗癌比較也有統(tǒng)計(jì)學(xué)差異(p0.05),而與腫瘤分化程度,淋巴結(jié)轉(zhuǎn)移以及TNM分期之間無(wú)統(tǒng)計(jì)學(xué)差異(p0.05)。EGFR基因突變與術(shù)前血清癌胚抗原檢測(cè)值有一定的相關(guān)性,有統(tǒng)計(jì)學(xué)意義(P0.05)。 結(jié)論：在新疆女性、肺腺癌患者中EGFR基因突變率為68.42%,為靶向治療提供有效的依據(jù)。術(shù)前血清癌胚抗原檢測(cè)值與EGFR基因突變具有一定的相關(guān)性,對(duì)無(wú)法檢測(cè)EGFR突變的NSCLC患者能否檢測(cè)癌胚抗原值來(lái)為靶向治療提供信息需要增加病例及進(jìn)行相關(guān)研究進(jìn)一步探討。
[Abstract]:Objective: to investigate the mutation of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) in Xinjiang and its correlation with clinicopathological features and tumor markers. Methods: Fifty-one patients with non-small cell lung cancer (NSCLC) after radical resection of lung cancer in the first affiliated Hospital of Xinjiang Medical University were selected to detect the exon of EGFR gene 18m19 / 2021 and other exons by fluorescence PCR assay. Serum carcinoembryonic antigen and other tumor markers were detected before operation. Results: the positive rate of EGFR was 49.02% (25 / 51), the mutation rate of exon 18 was 8% (2 / 25), the mutation rate of 19 was 52% (13 / 25), the mutation rate of 21 was 40% (10 / 25). The positive rate of male was 37.5% (12 / 32) and that of female was 68.42% (13 / 19). The positive rate in female patients was significantly higher than that in men (p0.05). There was also a significant difference between adenocarcinoma and adenosquamous carcinoma and squamous cell carcinoma (p0.05). There was no significant difference between lymph node metastasis and TNM stage (p0. 05). EGFR gene mutation was correlated with serum carcinoembryonic antigen detection value before operation (P0.05). Conclusion: in Xinjiang women, the mutation rate of EGFR gene in lung adenocarcinoma patients is 68.42, which provides an effective basis for targeted therapy. The detection value of serum carcinoembryonic antigen (CEA) was correlated with the mutation of EGFR gene. It is necessary to increase the number of patients with NSCLC who can not detect EGFR mutation to provide information for targeted therapy.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R734.2
本文編號(hào)：2291216
[Abstract]:Objective: to investigate the mutation of epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) in Xinjiang and its correlation with clinicopathological features and tumor markers. Methods: Fifty-one patients with non-small cell lung cancer (NSCLC) after radical resection of lung cancer in the first affiliated Hospital of Xinjiang Medical University were selected to detect the exon of EGFR gene 18m19 / 2021 and other exons by fluorescence PCR assay. Serum carcinoembryonic antigen and other tumor markers were detected before operation. Results: the positive rate of EGFR was 49.02% (25 / 51), the mutation rate of exon 18 was 8% (2 / 25), the mutation rate of 19 was 52% (13 / 25), the mutation rate of 21 was 40% (10 / 25). The positive rate of male was 37.5% (12 / 32) and that of female was 68.42% (13 / 19). The positive rate in female patients was significantly higher than that in men (p0.05). There was also a significant difference between adenocarcinoma and adenosquamous carcinoma and squamous cell carcinoma (p0.05). There was no significant difference between lymph node metastasis and TNM stage (p0. 05). EGFR gene mutation was correlated with serum carcinoembryonic antigen detection value before operation (P0.05). Conclusion: in Xinjiang women, the mutation rate of EGFR gene in lung adenocarcinoma patients is 68.42, which provides an effective basis for targeted therapy. The detection value of serum carcinoembryonic antigen (CEA) was correlated with the mutation of EGFR gene. It is necessary to increase the number of patients with NSCLC who can not detect EGFR mutation to provide information for targeted therapy.
【學(xué)位授予單位】：新疆醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2015
【分類號(hào)】：R734.2
【參考文獻(xiàn)】
相關(guān)期刊論文 前1條
1 黃光輝;杜娟;候襄河;羅教秀;唐渲;;表皮生長(zhǎng)因子受體基因突變表達(dá)與非小細(xì)胞肺癌分化程度關(guān)系的研究[J];分子診斷與治療雜志;2014年02期
，本文編號(hào)：2291216
本文鏈接：http://www.wukwdryxk.cn/yixuelunwen/zlx/2291216.html
最近更新
教材專著
